Current and past trends in life sciences deal-making activity

Posted by Michelle Choi on Fri, May 29, 2020

Cody Powers and Christopher Shapiro co-wrote this blog post with Michelle Choi.

Access COVID-19 resources

In our last blog post, we introduced a framework to assess the impact of COVID-19 on life sciences transaction activity. We noted that, in general, transaction volume declines following recessions and market uncertainty, but there’s evidence to suggest total deal value in these cases has been less affected vs. volume, with significant larger deals observed during prior down periods. In this post, we aim to further analyze these trends and assess how they can help inform the life sciences deal-making landscape today.


>
Read More

The Future of Data in Pharma: Data Privacy, Data Ownership and Going Beyond the Pill

Posted by ZS Editors on Wed, Feb 12, 2020

Remember when big data was big news? Now all we hear about is AI, but that hasn’t made data any less relevant. Data is the fuel that feeds the business and the future of pharma, let alone AI. The world is becoming more and more data dependent while slow, tectonic shifts are under way across healthcare: There’s an increasing focus on the value of medical care over volume. The patient experience is becoming a higher priority. Data privacy and data ownership concerns are constantly threatening to upend the status quo with regulations that could be hugely disruptive.


>
Read More

Boost Patient Recruitment With Data-Centric Trial Planning

Posted by Venkat Sethuraman on Fri, Aug 16, 2019

Denise N. Bronner, Gaurav A. Singh and Ray Zhong co-wrote this blog post with Venkat Sethuraman

A common struggle for pharmaceutical companies is poor patient recruitment for clinical trials. As a consequence, 80% of clinical trials fail to meet their enrollment goals, suffer delayed timelines and absorb skyrocketing R&D costs. Ultimately, the patient suffers from delays in the release of needed therapies. Currently, pharmaceutical companies are partnering with trial matching startups to enhance clinical study design, matching and data collection. With analytics and platforms, pharmaceutical companies are beginning to streamline the clinical trial process in hopes of increasing new entrants to the market.


>
Read More

A Panel of Experts Talk MDM in Healthcare: Three Takeaways

Posted by Ankit Jain on Mon, Jun 10, 2019

The potential of digital transformation is being realized across industries. In healthcare, advanced analytics has streamlined processes, sped up research and promises to drive better health outcomes. But advanced analytics are nothing without data, and unless you can break down data siloes across the enterprise and merge critical data into a single source of truth (otherwise known as master data management, or MDM), then your data will be insufficient to drive this kind of transformation.

I recently participated in a panel discussion for Informatica World 2019 with representatives from Intermountain Health and The American Cancer Society. We discussed MDM’s role in healthcare as a driver of digital transformation.

After reflecting on the conversation, I took three things away from the event:


>
Read More

Three Takeaways for Impactful Patient Marketing From Digital Pharma East

Posted by Greg Fry on Thu, Nov 01, 2018

As a member of the patient and consumer health team at ZS, I know that patients continue to expect easier access to better content. I was eager to hear how industry leaders were innovating to exceed those heightened expectations at the recent Digital Pharma East conference, which was held Oct. 16-19 in Philadelphia. 


>
Read More